Transforming Hematopoietic Stem Cell Transplant and Adoptive Cell Therapies
Shielded Cell & Immunotherapy Pairs™
Using our cell-shielding technology and precisely paired immunotherapies, we aim to significantly improve the eligibility and outcomes of hematopoietic stem cell transplants and adoptive cell therapy.
Our proprietary immunotherapies deplete diseased cells, while our cell-shielding technology protects healthy transplanted cells and allows them to engraft.
Because the transplanted cells are shielded, the immunotherapy can continue to be safely administered post-transplant to boost engraftment or treat minimal residual disease.
We use gene editing tools to insert novel protein variants into HSCs or other types of cells, allowing the cells to maintain their function while making them resistant to depletion by the paired immunotherapy.
Our shielding technology has proven to be effective in shielding cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells.